United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 4 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for CATALYST PHARMACEUTICALS, INC.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | |||
|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | 25.49% | 21.75% | 18.89% | 16.73% | 15.36% |
|---|---|---|---|---|---|
| ROA | 21.92% | 19.08% | 16.95% | 15.27% | 14.2% |
| Gross Margin | 86% | 85.04% | 84.86% | 84.49% | 84.54% |
| Net Margin | 36.39% | 36% | 34.58% | 34.05% | 34.14% |
| Total Assets | $1,103,979.00K | $1,336,816.31K | $1,584,379.19K | $1,846,224.40K | $2,128,509.60K |
| Net Income | $214,326.00K | $232,837.31K | $247,562.88K | $261,845.21K | $282,285.20K |